Home / Leaderboard / Kynam Capital Management, LP
Kynam Capital Management, LP
Yue Tang · Hedge Fund · Long/Short Equity
Kynam Capital Management, LP is an SEC-registered hedge fund manager based in Princeton, New Jersey, founded in 2020 by Yue "Derrick" Tang. The firm specializes in global healthcare and biotechnology investments, focusing primarily on the therapeutics sector. Kynam manages assets for institutional investors and high-net-worth individuals, employing a fundamental, research-driven approach to navigate the complexities of the life sciences industry. The firm is known for its sector-specific expertise and opportunistic investment style within the pharmaceutical and medical preparation markets.
Simulated Performance
| Metric | Value |
|---|---|
| Total return | +86.5% |
| YTD return | +15.6% |
| Sharpe ratio | 3.87 |
| Win rate | 73% |
| AUM | $1.6B |
| Inception | Oct 1, 2025 |
| Updated | Sep 4, 2026 |
Institution Status
| Field | Value |
|---|---|
| AUM | $1.6B |
| Turnover | Low (<15%) |
| Avg holding | 18 Months |
| Inception | Oct 1, 2025 |
| Website | https://www.kynamcap.com |
Current Holdings
Updated on Sep 4, 2026.
| Ticker | Name | Portfolio % | Return |
|---|---|---|---|
| CLDX | Celldex Therapeutics Inc | 13.3% | +53.3% |
| PCVX | Vaxcyte Inc | 11.0% | +34.4% |
| SNDX | Syndax Pharmaceuticals Inc | 10.0% | +15.7% |
| TVTX | Travere Therapeutics Inc | 8.3% | +33.6% |
| COGT | Cogent Biosciences Inc | 8.1% | +110.7% |
| URGN | UroGen Pharma Ltd | 6.7% | +43.5% |
| VERA | Vera Therapeutics Inc | 6.1% | +12.3% |
| BEAM | Beam Therapeutics Inc | 5.2% | +7.0% |
| CTMX | CytomX Therapeutics Inc | 4.5% | -12.8% |
| CGEM | Cullinan Oncology LLC | 4.2% | +63.0% |
| RLAY | Relay Therapeutics Inc | 3.9% | +15.7% |
| LEGN | Legend Biotech Corp | 3.8% | -14.6% |
| MBX | MBX Biosciences, Inc. Common Stock | 3.7% | +157.9% |
| IMCR | Immunocore Holdings Ltd | 3.1% | +2.7% |
| NRIX | Nurix Therapeutics Inc | 2.0% | +132.5% |
| BCRX | BioCryst Pharmaceuticals Inc | 1.5% | +30.1% |
| PHVS | Pharvaris BV | 1.5% | +20.1% |
| STRO | Sutro Biopharma | 1.1% | -39.6% |
| SMMT | Summit Therapeutics PLC | 1.0% | +28.2% |
| PRLD | Prelude Therapeutics Inc | 0.9% | -3.5% |
Recent activity
| Date | Action | Ticker | Weight |
|---|---|---|---|
| Aug 31, 2026 | SELL | CLDX | 13.0% → 13.3% |
| Aug 31, 2026 | SELL | PCVX | 10.5% → 11.0% |
| Aug 31, 2026 | BUY | NRIX | 1.7% → 2.0% |
| Aug 31, 2026 | SELL | BCRX | 3.3% → 1.5% |
| Aug 31, 2026 | BUY | TVTX | 5.6% → 8.3% |
Investment Style Analysis
Kynam Capital Management, LP is widely recognized for employing a Long/Short Equity strategy. As of Sep 4, 2026, the firm oversees approximately $1.6B in assets under management (AUM). The portfolio demonstrates a clear preference for the Biotechnology and Drug Manufacturers - Specialty & Generic sectors, reflecting a high-conviction approach to capital allocation.
Recent Market Moves
During the latest rebalancing period ending Aug 31, Kynam Capital Management, LP made a significant move by reducing the position in CLDX. This adjustment aligns with the fund's dynamic approach to risk management and capital deployment in current market conditions.
Investment Philosophy
Kynam Capital Management's investment philosophy is centered on achieving long-term risk-adjusted capital appreciation by focusing on global healthcare equities. The firm utilizes a deep-dive, fundamental analysis approach to identify high-conviction opportunities, particularly within the biotechnology and therapeutics industries. By leveraging robust scientific and financial research, Kynam employs a long/short equity strategy designed to generate alpha through concentrated positions and active risk management in a highly specialized and volatile market environment.
Disclaimer
The content provided on this page, including the simulated portfolio performance, holdings analysis, and AI-generated insights, is for informational and educational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any securities. All data is derived from historical SEC 13F filings and other public disclosures, which have a reporting lag. The "Simulated Performance" is a hypothetical reconstruction based on past disclosures and does not represent the actual returns of the institution. Past performance is not indicative of future results. Tritonix.ai is not affiliated with Kynam Capital Management, LP.
Similar Investment Style
Based on Long/Short Equity.
- Perceptive Advisors LLC — Joseph Edelman · 3M +34.8%
- Glenview Capital Management, LLC — Larry Robbins · 3M +15.8%
- Zweig-DiMenna Associates, Inc. — Joseph DiMenna · 3M +5.8%
- Redmile Group, LLC — Jeremy Green · 3M +29.9%
Frequently asked questions
How is the simulated portfolio for Kynam Capital Management, LP constructed?
This simulation is powered by Tritonix AI using official SEC filings. We focus on the "Best Ideas" by filtering for only the Top 20 largest holdings and rebalancing them to 100%. The simulation tracks performance starting from Oct 1, 2025. Our AI monitors for updates every Monday to capture major shifts. This concentrated approach highlights the manager's true stock-picking skill and mirrors their actual investment returns.
What is Kynam Capital Management, LP's largest holding?
As of the latest filing, Kynam Capital Management, LP's top position is Celldex Therapeutics Inc (CLDX), representing 13.3% of the portfolio. This reflects a high-conviction bet by the institution.
What is Kynam Capital Management, LP's historical performance and risk profile?
Our simulation indicates a total return of +86.5% with a win rate of 73%. Notably, the portfolio maintains a Sharpe Ratio of 3.87, suggesting an exceptional level of risk-adjusted returns compared to the broader market.
What sectors does Kynam Capital Management, LP primarily invest in?
Kynam Capital Management, LP has a strong preference for the Biotechnology sector, which makes up 98.5% of their disclosed assets. The portfolio also has exposure to Drug Manufacturers - Specialty & Generic, indicating a specific thematic focus.
Is Kynam Capital Management, LP's portfolio concentrated or diversified?
Kynam Capital Management, LP runs a moderately concentrated portfolio with 20 disclosed positions. The top 3 holdings alone account for 34.3% of the total portfolio weight, suggesting a strategy that favors broader market exposure.
How has Kynam Capital Management, LP performed in 2026?
Our AI-simulated model portfolio for Kynam Capital Management, LP tracks a Year-to-Date (YTD) return of +15.6%. This metric helps investors gauge the institution's effectiveness in the current market environment.
Does Yue Tang manage Kynam Capital Management, LP directly?
Yes, Yue Tang serves as the key portfolio manager for Kynam Capital Management, LP, overseeing the investment strategy and final capital allocation decisions.